While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was to evaluate the risk of heart failure hospitalization (hHF) among AA vs. White (Wh) vs. Hispanic (His) patients with type 2 diabetes (T2D) initially prescribed empagliflozin (EMPA) .
We performed a multicenter retrospective study that extracted real world data for patients with T2D from 4 institutions in North & South Carolina who were ≥ 18 years, either AA or Wh or His, & were prescribed EMPA between Aug 2014 & Dec 2019. Our 1ry outcome was time to first hHF. Cumulative probability of hHF by race was estimated using the cumulative incidence function. The association of race with risk of hHF was evaluated using multivariable Cox hazards model.
A total of 9708 patients were eligible. Of these, 8994 patients had no history of hHF prior to EMPA administration (incident cohort) . Baseline characteristics & results are summarized in Table 1. AA patients were significantly younger, predominantly female, less likely to have pre-existing cardiac conditions, & more likely to have hypertension. When adjusting for age, gender, & baseline comorbidities, there was no significant difference in the risk of hHF between AA vs. Wh or His vs Wh.
Although clinical trials often misrepresent minorities, using real world data we found no significant difference in the risk of hHF in AA or His versus Wh patients with T2D taking EMPA.
B. M. Mishriky: Advisory Panel; AstraZeneca, AstraZeneca, Bayer AG, Bayer AG, Other Relationship; Lilly, Research Support; Lilly. A. Adams: None. W. Irish: Consultant; Eurofins Transplant Genomics, Taleris. D. M. Cummings: None. Y. Fu: None. J. Halladay: None. W. S. Jones: Research Support; Boehringer Ingelheim International GmbH. A. Boan: None. S. Jones berkeley: None. S. P. Patil: Research Support; Novo Nordisk. J. R. Powell: None.
Brody Brothers Endowment Grant (20-0922)